Department of Cardiac and Vascular Disease, John Paul II Hospital, Jagiellonian University Medical College, Kraków, Poland.
Tufts Medical Center, Boston, USA.
Adv Clin Exp Med. 2021 Mar;30(3):245-253. doi: 10.17219/acem/115081.
Galectin-3 is an emerging biomarker in cardiovascular disease. Myocardial galectin-3 is involved in the pathology of cardiac fibrosis; however, the role of circulating galectin-3 is not yet established.
To assess the relationships between circulating galectin-3, fibrosis and outcomes in dilated cardiomyopathy (DCM).
We included 70 patients (age: 48 ±12.1 years, ejection fraction (EF) 24.4 ±7.4%) with new-onset DCM (n = 35, ≤6 months). Galectin-3 and procollagen type I and III (PICP, PINP, PIIICP, and PIIINP), transforming growth factor β (TGF-β), connective tissue growth factor (CTGF), osteopontin (OPN), matrix metalloproteinases (MMP-2 and -9), and tissue inhibitor (TIMP-1) were determined in serum at baseline and after 3 and 12 months. Patients underwent endomyocardial biopsy. The endpoint was a combination of death and urgent hospitalization at 12 months.
Galectin-3 did not correlate with biopsy-determined fibrosis. Baseline galectin-3 correlated with OPN,, TIMP-1, PIIICP, and MMP-2. In new-onset DCM, galectin-3 levels at baseline were higher than at 3 and 12 months, whereas in chronic DCM there was no difference. Galectin-3 was a predictor of the endpoint (hazard ratio (HR) = 1.115; 95% confidence interval (95% CI) = 1.009-1.231; p < 0.05). The best cut-off value was 14.54 ng/mL (area under the curve (AUC) = 0.67). Patients with galectin-3 ≥14.54 ng/mL had an increased risk of events (HR = 2.569; 95% CI = 1.098-6.009; p < 0.05).
Circulating galectin-3 is unrelated to fibrosis. Serial measurements of galectin-3 correlated with markers of fibrosis, including markers of collagen synthesis and OPN. Circulating galectin-3 was independently associated with cardiovascular (CV) outcomes in DCM.
半乳糖凝集素-3 是心血管疾病中一种新兴的生物标志物。心肌中的半乳糖凝集素-3 参与了心肌纤维化的病理过程；然而，循环中的半乳糖凝集素-3 的作用尚未确定。
评估循环半乳糖凝集素-3 与扩张型心肌病（DCM）中的纤维化和结局之间的关系。
我们纳入了 70 名新发 DCM 患者（年龄：48 ± 12.1 岁，射血分数（EF）24.4 ± 7.4%）（n = 35，≤6 个月）。在基线时以及 3 个月和 12 个月时，血清中半乳糖凝集素-3 以及前胶原 I 和 III（PICP、PINP、PIIICP 和 PIIINP）、转化生长因子-β（TGF-β）、结缔组织生长因子（CTGF）、骨桥蛋白（OPN）、基质金属蛋白酶（MMP-2 和 -9）和组织抑制剂（TIMP-1）进行了测定。患者接受了心内膜心肌活检。终点是 12 个月时死亡和紧急住院的组合。
半乳糖凝集素-3 与活检确定的纤维化无关。基线半乳糖凝集素-3 与 OPN、TIMP-1、PIIICP 和 MMP-2 相关。在新发 DCM 中，基线时的半乳糖凝集素-3 水平高于 3 个月和 12 个月时，而在慢性 DCM 中则没有差异。半乳糖凝集素-3 是终点的预测因子（危险比（HR）= 1.115；95%置信区间（95%CI）= 1.009-1.231；p < 0.05）。最佳截断值为 14.54ng/mL（曲线下面积（AUC）= 0.67）。半乳糖凝集素-3≥14.54ng/mL 的患者发生事件的风险增加（HR = 2.569；95%CI = 1.098-6.009；p < 0.05）。
循环半乳糖凝集素-3 与纤维化无关。半乳糖凝集素-3 的连续测量与纤维化标志物相关，包括胶原合成标志物和 OPN。循环半乳糖凝集素-3 与 DCM 中的心血管（CV）结局独立相关。
